Literature DB >> 8100912

Emergence of vancomycin-resistant enterococci in New York City.

T R Frieden1, S S Munsiff, D E Low, B M Willey, G Williams, Y Faur, W Eisner, S Warren, B Kreiswirth.   

Abstract

Enterococci, a common cause of nosocomial infection, are intrinsically resistant to most antimicrobials and readily acquire additional resistance. Vancomycin-resistant enterococci (VRE) have caused clusters of nosocomial infections since 1988. In April, 1991, the New York City Department of Health asked all city laboratories to submit suspected VRE isolates for confirmation. Clinical and epidemiological characteristics of the first 100 patients with VRE were identified, and antimicrobial susceptibility testing, restriction enzyme analysis, and DNA-DNA hybridisation with the vanA gene probe were done. From September, 1989, to October, 1991, 361 patients with VRE were identified at 38 hospitals. The number of hospitals reporting VRE increased from 1 in 1989 to 38 by October, 1991. 98% of 100 VRE infections were nosocomially acquired and 83% patients had received vancomycin and/or a cephalosporin in the 30 days before isolation of VRE. Of 23 isolates from 21 of the first 100 patients, 19 (83%) were resistant to all available antimicrobials. Four vanA probing patterns were noted, and restriction enzyme analysis of the 23 isolates revealed 14 strains. VRE have emerged rapidly in New York City. Molecular analyses suggest that a highly mobile genetic element--eg, a transposon--is responsible for the rapid spread of vancomycin resistance.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100912     DOI: 10.1016/0140-6736(93)91285-t

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  59 in total

1.  High prevalence of vancomycin-resistant enterococci in Swedish sewage.

Authors:  Aina Iversen; Inger Kühn; Anders Franklin; Roland Möllby
Journal:  Appl Environ Microbiol       Date:  2002-06       Impact factor: 4.792

Review 2.  Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci.

Authors:  Stephan Harbarth; Sara Cosgrove; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

3.  Molecular epidemiology and antibiotic susceptibility of enterococci in Cincinnati, Ohio: a prospective citywide survey.

Authors:  D E Perlada; A G Smulian; M T Cushion
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

Review 4.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

5.  An Update on the Emergence of Glycopeptide Resistance in Enterococci.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

6.  Prevalence of vancomycin-resistant enterococci in fecal samples from hospitalized patients and nonhospitalized controls in a cattle-rearing area of France.

Authors:  K Gambarotto; M C Ploy; P Turlure; C Grélaud; C Martin; D Bordessoule; F Denis
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

7.  [S2 Guideline for diagnosis and therapy of infectious endocarditis].

Authors:  C K Naber
Journal:  Z Kardiol       Date:  2004-12

8.  A 24-hour screening protocol for identification of vancomycin-resistant Enterococcus faecium.

Authors:  Steven J Drews; Grant Johnson; Farhad Gharabaghi; Margaret Roscoe; Anne Matlow; Raymond Tellier; Susan E Richardson
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

9.  Are clinical laboratories in California accurately reporting vancomycin-resistant enterococci?

Authors:  J Rosenberg; F C Tenover; J Wong; W Jarvis; D J Vugia
Journal:  J Clin Microbiol       Date:  1997-10       Impact factor: 5.948

10.  Reducing vancomycin use utilizing a computer guideline: results of a randomized controlled trial.

Authors:  K G Shojania; D Yokoe; R Platt; J Fiskio; N Ma'luf; D W Bates
Journal:  J Am Med Inform Assoc       Date:  1998 Nov-Dec       Impact factor: 4.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.